Successful treatment with erlotinib after gefitinib-induced severe interstitial lung disease

Journal of Thoracic Oncology

Volumn 5, Issue 7, 2010, Pages 1103-1104

  Takeda, Masayuki ^a   Okamoto, Isamu ^a   Makimura, Chihiro ^a   Fukuoka, Masahiro ^a   Nakagawa, Kazuhiko ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; METHYLPREDNISOLONE; ANTINEOPLASTIC AGENT; QUINAZOLINE DERIVATIVE;

ADULT; ARTICLE; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CARCINOMATOUS MENINGITIS; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DISEASE SEVERITY; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; EXON; FEMALE; FEVER; FOLLOW UP; GENE DELETION; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG ADENOCARCINOMA; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; NEEDLE BIOPSY; PRIORITY JOURNAL; CHEMICALLY INDUCED; LUNG NEOPLASMS; MIDDLE AGED; PATHOLOGY; SURVIVAL RATE; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; LUNG DISEASES, INTERSTITIAL; LUNG NEOPLASMS; MIDDLE AGED; QUINAZOLINES; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 77954420916     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181d89ac2     Document Type: Article

References (5)

1. Ando M, Okamoto I, Yamamoto N, et al. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2006;24:2549-2556. (Pubitemid 46630633)
2. Tamura K, Okamoto I, Kashii T, et al. Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403). Br J Cancer 2008;98:907-914. (Pubitemid 351341609)
3. Hardie WD, Prows DR, Leikauf GD, et al. Attenuation of acute lung injury in transgenic mice expressing human transforming growth factor-alpha. Am J Physiol 1999;277:L1045-L1050.
4. Hardie WD, Prows DR, Piljan-Gentle A, et al. Dose-related protection from nickel-induced lung injury in transgenic mice expressing human transforming growth factor-alpha. Am J Respir Cell Mol Biol 2002;26: 430-437. (Pubitemid 34253927)
5. Suzuki H, Aoshiba K, Yokohori N, et al. Epidermal growth factor receptor tyrosine kinase inhibition augments a murine model of pulmonary fibrosis. Cancer Res 2003;63:5054-5059. (Pubitemid 37025129)